메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류
인문학
인문학 일반 역사학 철학 종교학 어문학 기타 인문학
사회과학
사회과학 일반 경영학 관광학 교육학 군사학 문헌정보학 법학 사회학 신문방송학 심리과학 정치외교학 지리학 행정학 경제학 무역학 인류학 기타 사회과학
자연과학
자연과학 일반 물리학 생물학 생활과학 수학·통계학 천문학 지구과학 화학 기타 자연과학
공학
공학 일반 건축공학 기계공학 산업공학 재료·에너지공학 전기전자공학 조선해양공학 화학공학 컴퓨터학 기타공학
의약학
의학 일반 간호학 수의학 약학 한의학 기초의학 임상의학 기타 의약학
농수해양학
농수해양학 일반 농학 수산학 식품과학 임학 축산학 해상운송학 기타 농수해양학
예술체육학
예술 일반 디자인 미술 미용 사진 음악학 의상 체육 공연매체예술 기타 예술체육학
복합학
학제간연구 과학기술학 뇌인지과학 기술정책 기타 복합학

ENG

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Kwang Hyun Choi (Korea Cancer Center Hospital) Chan Sub Park (Korea Cancer Center Hospital) Sang Hee Kim (Korea Cancer Center Hospital) Na Won Kim (Korea Cancer Center Hospital) Juhyeon Lee (Korea Cancer Center Hospital) Ji Yea Kim (Korea Institute of Radiological and Medical Science) In-Chul Park (Korea Institute of Radiological and Medical Science) Min Ki Seong (Korea Cancer Center Hospital) Hyun-Ah Kim (Korea Cancer Center Hospital) Woo Chul Noh (Konkuk University Medical Center)
저널정보
한국유방암학회 Journal of Breast Disease Journal of Breast Disease 제9권 제2호
발행연도
2021.12
수록면
65 - 70 (6page)
DOI
10.14449/jbd.2021.9.2.65

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose: Endocrine therapy is the first-line treatment recommended for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer without visceral crisis. However, this recommendation has not been followed clinically because of efficacy issues. In this study, the survival of patients with HR-positive/HER2-negative metastatic breast cancer was evaluated based on the following first-line treatment regimens: the combination of palbociclib plus letrozole, conventional endocrine therapy, or chemotherapy. Methods: Medical records were reviewed for this retrospective analysis. Patients with HR-positive/HER2-negative metastatic breast cancer were included. Progression-free survival (PFS) and overall survival (OS) were compared based on first-line treatment regimens. Results: A total of 184 patients were included in the analysis. The first-line treatments were palbociclib plus letrozole in 46 patients (25.0%), endocrine therapy in 40 patients (21.7%), and chemotherapy in 98 patients (53.3%). The PFS of the palbociclib plus letrozole group was significantly longer than that of the endocrine therapy (hazard ratio=3.43, p<0.001) and chemotherapy (hazard ratio=2.88, p=0.001) groups. No significant difference was observed between the endocrine therapy and chemotherapy groups (p=0.430). The OS of the palbociclib plus letrozole group was significantly longer than that of the endocrine therapy (hazard ratio=5.34, p=0.009) and chemotherapy (hazard ratio 4.23, p=0.043) groups. No significant difference was observed between the endocrine therapy and chemotherapy groups (p=0.451). Conclusion: The combination regimen of palbociclib and letrozole could be recommended as the first-line treatment of choice in patients with HR-positive/HER2-negative metastatic breast cancer.
#Breast neoplasms #Cyclin-dependent kinases #Letrozole #Progression-free survival #Survival

목차

등록된 정보가 없습니다.

참고문헌 (15)

참고문헌 신청
Jacquet E / 2018 / Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients / Eur J Cancer 95:93~101 google schola Rugo HS / 2016 / Endocrine therapy for hormone receptor-positive metastatic breast cancer : American Society of Clinical Oncology Guideline / J Clin Oncol 34:3069~3103 google schola Paluch-Shimon S / 2016 / Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes : ESMO Clinical Practice Guidelines for cancer prevention and screening / Ann Oncol 27:v103~10 google schola Gradishar WJ / 2020 / Breast cancer, version 3.2020, NCCN Clinical Practice Guidelines in Oncology / J Natl Compr Canc Netw 18:452~478 google schola Swallow E / 2014 / Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive(HR+)/human epidermal growth factor receptor-2-negative(HER2-)breast cancer patients in the United States : 2002-2012 / Curr Med Res Opin 30:1537~1545 google schola

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0